Immix Bio：组织特异性多激酶抑制剂公司申请IPO上市 - 雪球
2021年9月27日 · imx-110通过阻断多种激酶，干扰nf-κb 和stat3活化，阻断炎症周期中的正反馈循环，阻断肿瘤持续性炎症。 IMX-110目前处在临床1b/2a期，开发指征为软肉瘤，截止2021 …
Immix Biopharma Announces Early Positive IMX-110 Interim …
2023年5月3日 · The novel approach combining TSTx IMX-110 with anti-PD-1 antibody tislelizumab is designed to expand the population of cancer patients experiencing extended …
IMX-110/Tislelizumab Yields Notable Tumor Shrinkage in Two …
2023年5月5日 · Investigational agent IMX-110 plus tislelizumab resulted in tumor shrinkage at 2 months in patients with advanced metastatic colorectal cancer (CRC), according to a press …
ImmixBio Announces FDA Orphan Drug Designation for IMX-110 …
2021年9月30日 · IMX-110 is a Tissue-Specific Therapeutic TM built on ImmixBio's TME Normalization TM Technology encapsulating a poly-kinase inhibitor and apoptosis inducer …
Immix Biopharma Announces 16th Patient Dosing in Ongoing …
2022年12月20日 · This patient has a relapsed/refractory pecoma, a rare form of soft tissue sarcoma, a connective tissue cancer. IMX-110 clinical trial data is expected to be released on …
IMX-110 + anti-PD-1 Combination Produced Extended Median
2022年1月25日 · Our lead asset IMX-110, currently in Phase 1b/2a clinical trials, holds orphan drug designation (ODD) by the FDA for soft tissue sarcoma, and has received Rare Pediatric …
ImmixBio Announces Positive IMX-110 Phase 1b/2a Interim
2022年1月19日 · Our lead asset IMX-110, currently in Phase 1b/2a clinical trials, holds orphan drug designation (ODD) by the FDA for soft tissue sarcoma, and has received Rare Pediatric …
Immix Biopharma Announces Dosing of First 2 Patients in its IMX-110 …
2023年2月7日 · Immix Biopharma, Inc. today announced dosing of the first 2 patients in its IMX-110 + Beigene/Novartis anti-PD-1 Tislelizumab Combination Phase 1b/2a Clinical Trial in …
IMX Chemal Gegg Linda — Yandex:found 5 thousand results
Imx To Chemal Gegg Sarah Model Set 107 X28 33843565. ... Chemal Gegg Linda 2 Chemal And Gegg Flora Model Set 38 Download. Chemal Gegg- Linda - Chemal & Gegg - Page 3 - …
IMX-110 Plus Tislelizumab Leads to Tumor Shrinkage in Heavily
2023年7月19日 · Treatment with the combination of the tissue-specific therapeutic IMX-110 and the anti–PD-1 antibody tislelizumab led to tumor shrinkage in heavily pretreated patients with …
- 某些结果已被删除